Sterling Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Sterling Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-621	Closed	-$1.05K	–	3287
2026 Q1	$1.05K	Sell	621 -363	-37%	-$1.59K	﹤0.01%	3091
2025 Q4	$5.1K	Buy	984 +180	+22%	+$925	﹤0.01%	2887
2025 Q3	$4.2K	Buy	804 +424	+112%	+$2.21K	﹤0.01%	2808
2025 Q2	$1.46K	Sell	380 -397	-51%	-$1.03K	﹤0.01%	2993
2025 Q1	$4.47K	Sell	777 -661	-46%	-$3.91K	﹤0.01%	2226
2024 Q4	$7.18K	Buy	1,438 +1,291	+878%	+$6.62K	﹤0.01%	2304
2024 Q3	$792	Buy	+147	New	+$700	﹤0.01%	2659

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Sterling Capital Management's ALDX Position: Q2 2026 in Review

Sterling Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 621 shares — an estimated $1.05K sold.

Sterling Capital Management first reported a position in ALDX in Q3 2024 and held it in 7 quarters. The position peaked at $7.18K in Q4 2024. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Sterling Capital Management reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
Sterling Capital Management sold 621 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.05K.
Sterling Capital Management first reported a position in Aldeyra Therapeutics in Q3 2024 and held it in 7 quarters.
Sterling Capital Management's Aldeyra Therapeutics position peaked at $7.18K in Q4 2024.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.